In particular, ipilimumab, a human monoclonal antibody that blocks cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), has been associated with improved survival in patients with metastatic melanoma [43]. Here, CTLA4 is linked to metastatic melanoma.